Sonoma Pharmaceuticals, Inc. (SNOA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Sonoma Pharmaceuticals, Inc. is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, podiatry, animal health, and disinfection. The company operates in over 55 countries and is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $6.41 million | $4.02 million |
| Gross Profit | $2.58 million | $1.46 million |
| Gross Margin | 40% | 36% |
| Net Loss | $(0.33) million | $(1.24) million |
| Net Loss Per Share (Basic/Diluted) | $(0.09) | $(0.76) |
| Cash and Cash Equivalents (End of Period) | $5.34 million | $3.61 million |
| Working Capital | $10.82 million | $8.26 million |
| Short-Term Debt | $0.14 million | N/A |
| Accumulated Deficit | $(201.31) million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 60% year-over-year, driven primarily by a 141% surge in U.S. sales due to increased over-the-counter product sales and new distributor activity. Europe and Asia also saw significant growth (34% and 37%, respectively).
- Profitability Improvement: The net loss narrowed significantly from $1.24 million to $0.33 million. Gross margin expanded to 40% from 36% due to manufacturing process improvements and favorable customer mix.
- Capital Raise: In April 2026, the company completed a public offering, issuing approximately 2.96 million shares (including pre-funded warrants) for net proceeds of $3.48 million. This significantly bolstered liquidity.
- Cash Flow: Net cash used in operating activities improved to $0.65 million from $2.02 million in the prior year. Financing activities provided $3.45 million in cash, primarily from the equity offering.
Outlook, Risks, and Contingencies
- Liquidity: Management believes existing cash and recent proceeds are sufficient to fund operations for at least the next 12 months. The company maintains access to capital markets but notes no assurance of future financing terms.
- Significant Tax Contingency: The company faces a substantial potential tax liability in Mexico related to intercompany loans and technical assistance charges. Outstanding principal and accrued interest total approximately $46.7 million. If the debt is forgiven or converted, the company estimates a potential Mexico income tax liability of approximately $17.2 million plus 15% withholding tax. The company currently cannot claim credits for these withholding taxes due to U.S. net operating losses.
- Customer Concentration: Revenue remains concentrated among a few key customers. In Q1 2026, two customers (Customer C and Customer E) each accounted for 18% of total revenue.
- Listing Risk: The company faces a new Nasdaq requirement for a minimum Market Value of Listed Securities of $5 million. Failure to maintain this could result in delisting.
- Foreign Exchange: The company is exposed to currency fluctuations, particularly regarding the Mexican Peso and Euro, which impacted "Other expense, net" in the current quarter.
Investor Verification Checklist
- Verify the status and potential resolution of the $17.2 million+ Mexico tax liability and the company's strategy for managing the intercompany debt maturing in 2032.
- Monitor compliance with the new Nasdaq $5 million Market Value of Listed Securities requirement to avoid delisting.
- Assess the sustainability of the 141% U.S. revenue growth and the impact of the new Medline distribution agreement on future margins.
- Review the customer concentration risk, noting that 36% of revenue came from just two customers in Q1 2026.
- Confirm the timeline for cash burn relative to the $5.34 million cash balance, given the historical operating cash outflows.